Prophylactic Treatment With Atorvastatin for Episodic Migraine.
Status:
RECRUITING
Trial end date:
2029-02-28
Target enrollment:
Participant gender:
Summary
The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) there is an effect of a daily dose of 20mg Atorvastatin, 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 3) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.
Phase:
PHASE2
Details
Lead Sponsor:
St. Olavs Hospital
Collaborators:
Haukeland University Hospital Oslo University Hospital Ullevaal University Hospital University Hospital of North Norway University Hospital, Akershus